About Lanesurf AI

This startup develops optimized AI models specifically for drug discovery, accelerating R&D for pharmaceutical companies. Their system offers features like protein and enzyme design, antibody engineering, and small molecule discovery, streamlining the drug development process.

```xml <problem> Traditional protein engineering methods often involve extensive experimentation and fail to fully capture epistatic effects, leading to suboptimal protein variants and prolonged R&D cycles. Optimizing multiple protein properties simultaneously, such as activity, stability, and solubility, presents a significant challenge with conventional techniques. </problem> <solution> BioChest offers an AI-powered platform that accelerates biotech R&D by predicting improved protein variants with fewer experiments. Their machine learning models learn from experimental data to overcome epistasis and optimize multiple properties concurrently. The platform enables scientists to identify high-value mutations, reduce experimental iterations, and achieve project goals faster. BioChest's technology is applicable to enzyme, antibody, and peptide design, allowing for the optimization of properties such as thermostability, activity, solubility, and expression. </solution> <features> - Experimentally validated machine learning models that overcome epistasis. - Multi-property optimization, allowing for simultaneous improvement of stability, activity, and other desired characteristics. - AI-driven prioritization of protein variants to reduce the number of experimental rounds needed. - Support for enzyme design, including optimization of activity, thermostability, solubility, and solvent stability. - Capabilities for antibody design, focusing on affinity, thermostability, solubility, solvent stability, and expression. - Peptide design features, including optimization of affinity, stability, solubility, and cell penetration. </features> <target_audience> BioChest targets scientists and researchers in the biotechnology and pharmaceutical industries who are involved in protein engineering, enzyme design, antibody development, and peptide engineering. </target_audience> ```

What does Lanesurf AI do?

Where is Lanesurf AI located?

Lanesurf AI is based in San Francisco, United States.

When was Lanesurf AI founded?

Lanesurf AI was founded in 2023.

Location

San Francisco, United States

Founded

2023

Employees

2 employees

Lanesurf AI

Relative Traction Score based on online presence metrics compared to companies in the same age group.

Lanesurf AI

Relative Traction Score based on online presence metrics compared to companies in the same age group.

Executive Summary

biochestcloud.com 500+

Founded 2023 – San Francisco, United States

Funding

No funding information available.

Team (<5)

No team information available.

Company Description

Problem

Traditional protein engineering methods often involve extensive experimentation and fail to fully capture epistatic effects, leading to suboptimal protein variants and prolonged R&D cycles. Optimizing multiple protein properties simultaneously, such as activity, stability, and solubility, presents a significant challenge with conventional techniques.

Solution

BioChest offers an AI-powered platform that accelerates biotech R&D by predicting improved protein variants with fewer experiments. Their machine learning models learn from experimental data to overcome epistasis and optimize multiple properties concurrently. The platform enables scientists to identify high-value mutations, reduce experimental iterations, and achieve project goals faster. BioChest's technology is applicable to enzyme, antibody, and peptide design, allowing for the optimization of properties such as thermostability, activity, solubility, and expression.

Features

Experimentally validated machine learning models that overcome epistasis.

Multi-property optimization, allowing for simultaneous improvement of stability, activity, and other desired characteristics.

AI-driven prioritization of protein variants to reduce the number of experimental rounds needed.

Support for enzyme design, including optimization of activity, thermostability, solubility, and solvent stability.

Capabilities for antibody design, focusing on affinity, thermostability, solubility, solvent stability, and expression.

Peptide design features, including optimization of affinity, stability, solubility, and cell penetration.

Target Audience

BioChest targets scientists and researchers in the biotechnology and pharmaceutical industries who are involved in protein engineering, enzyme design, antibody development, and peptide engineering.

Sources: